载药微球治疗原发性肝癌的研究进展  

Research progress of drug-loaded microspheres in treatment of primary liver cancer

作　　者：苗颖 MIAO Ying(Intervention Room of Affiliated Hospital of Guilin Medical College,Guangxi,Guilin 541001,China)

机构地区：[1]桂林医学院附属医院介入室,广西壮族自治区桂林市541001

出　　处：《河北医药》2022年第14期2198-2202,共5页Hebei Medical Journal

基　　金：广西壮族自治区卫生健康委员会自筹经费科研课题(Z20190518)。

摘　　要：经动脉化疗栓塞(TACE)作为成熟的技术广泛应用于治疗原发性肝癌已经有30多年的时间。目前TACE是无法行根治手术PLC患者的首选治疗,在原发性肝癌诊疗规范(2019年版)中TACE适用于中国肝癌分期方案(China liver cancer staging,CNLC)中Ⅰb~Ⅲb期。临床上TACE治疗根据栓塞材料不同主要分为传统TACE(cTACE)和载药微球TACE(DEB-TACE)。DEB-TACE使用载药微球这一种新型的栓塞材料与cTACE(使用碘化油乳剂作为栓塞材料)在药物代谢动力学方面有较大不同,且方案也无统一标准。鉴于此,本文对于在临床中接诊原发性肝癌疾病患者采用DEB-TACE重要特点及研究进展进行综述。Transarterial chemoembolization(TACE),as a mature technology,has been widely used to treat primary liver cancer(PLC)for more than 30 years.At present,TACE is the first choice for the patients with PLC who cannot receive radical surgery.In the diagnosis and treatment standard for primary liver cancer(2019 edition),TACE is applicable to stageⅠb~Ⅲb in China liver cancer staging scheme(CNLC).Clinical TACE treatment is mainly divided into cTACE and DEB-TACE according to different embolic materials.DEB-TACE,a new embolic material using drug-loaded microspheres,is quite different from cTACE(using iodinated oil emulsion as embolic material)in terms of pharmacokinetics,and there is no uniform standard for the scheme.In view of this,this article reviews the important characteristics and research progress of adopting DEB-TACE in clinical treatment of primary liver cancer.

关 键 词：原发性肝癌 经动脉化疗栓塞术 CalliSpheres载药微球 碘化油乳剂 

分 类 号：R735.7[医药卫生—肿瘤]